Editorial
Published on 02 Dec 2024
Editorial: DNA methylation in cancer therapy: therapeutic targets and molecular mechanism
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2024.1508214
- 507 views
Type at least 3 characters
1,051 articles
Correction
Published on 27 Nov 2024
Corrigendum: Chamaejasmin B decreases malignant characteristics of mouse melanoma B16F0 and B16F10 cells
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2024.1472829
- 405 views
Correction
Published on 25 Nov 2024
Corrigendum: Long non-coding RNA SNHG1 regulates the Wnt/β-catenin and PI3K/AKT/mTOR signaling pathways via EZH2 to affect the proliferation, apoptosis, and autophagy of prostate cancer cell
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2024.1501882
- 891 views
Review
Published on 25 Nov 2024
Long noncoding RNA mediates enzalutamide resistance and transformation in neuroendocrine prostate cancer
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2024.1481777
- 1,352 views
Case Report
Published on 20 Nov 2024
Case report: Tracing in parallel the salivary and gut microbiota profiles to assist Larotrectinib anticancer treatment for NTRK fusion–positive glioblastoma
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2024.1458990
- 1,189 views
Review
Published on 12 Nov 2024
Current insights on m6A RNA modification in acute leukemia: therapeutic targets and future prospects
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2024.1445794
- 1,060 views
Original Research
Published on 08 Nov 2024
Mechanism of luteolin against non-small-cell lung cancer: a study based on network pharmacology, molecular docking, molecular dynamics simulation, and in vitro experiments
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2024.1471109
- 1,859 views
Correction
Published on 28 Oct 2024
Corrigendum: Dietary polyphenols, resveratrol and pterostilbene exhibit antitumor activity on an HPV E6-positive cervical cancer model: an in vitro and in vivo analysis
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2024.1483410
- 561 views
Review
Published on 23 Oct 2024
Curcumin as a novel therapeutic candidate for cancer: can this natural compound revolutionize cancer treatment?
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2024.1438040
- 2,762 views
- 3 citations
Editorial
Published on 18 Oct 2024
Editorial: Novel drug discovery and design in acute myeloid leukemia: from bench to bedside
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2024.1449636
- 727 views
Original Research
Published on 18 Oct 2024
Identification and validation of matrix metalloproteinase hub genes as potential biomarkers for Skin Cutaneous Melanoma
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2024.1471267
- 1,409 views
- 1 citation
Editorial
Published on 10 Oct 2024
Editorial: Metals in cancer: from intracellular signaling to therapy
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2024.1495825
- 481 views
- 1 citation
Original Research
Published on 10 Oct 2024
Roburic acid inhibits lung cancer metastasis and triggers autophagy as verified by network pharmacology, molecular docking techniques and experiments
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2024.1449143
- 1,408 views
Review
Published on 09 Oct 2024
From defense to offense: antimicrobial peptides as promising therapeutics for cancer
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2024.1463088
- 2,404 views
- 3 citations
Systematic Review
Published on 30 Sep 2024
Administration sequences in single-day chemotherapy regimens for breast cancer: a comprehensive review from a practical perspective
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2024.1353067
- 1,804 views
- 1 citation
Correction
Published on 30 Sep 2024
Corrigendum: 5-Demethylnobiletin mediates cell cycle arrest and apoptosis via the ERK1/2/AKT/STAT3 signaling pathways in glioblastoma cells
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2024.1494738
- 703 views